Amphastar Pharmaceuticals (AMPH) News Today

Bessemer Group Inc. grew its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 21.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 395,941 shares of the company's stock after

Hillsdale Investment Management Inc. reduced its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 59.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,279 shares of the c

Concurrent Investment Advisors LLC bought a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 15,778 shares of the company's stock, valued at approximately $693,000. A n

LSV Asset Management lowered its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 29.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 224,768 shares of the company's stock after selling 92,832 shares during the p

Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 12-Month Low at $37.14

Vanguard Group Inc. raised its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 1.7% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 2,815,596 shares of the company's stock after purchasing an additional 48,203

Allspring Global Investments Holdings LLC grew its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 61.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 64,564 shares of the company's s

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) was the target of a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 4,150,000 shares, an increase of 10.4% from the May 31st total of 3,760,000 shares. Based on an average daily volume of 341,900 shares, the short-interest ratio is presently 12.1 days. Currently, 11.8% of the company's shares are sold short.

Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 12-Month Low on Insider Selling

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) CFO William J. Peters sold 3,596 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $40.93, for a total transaction of $147,184.28. Following the completion of the transaction, the chief financial officer now directly owns 94,103 shares in the company, valued at $3,851,635.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) have received a consensus rating of "Moderate Buy" from the five research firms that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and thr

Piper Sandler reissued an "overweight" rating and set a $71.00 price objective on shares of Amphastar Pharmaceuticals in a report on Thursday.

Will the market get interest rate cuts at all this year? That is the question that looms over most investors' shoulders today.

These 2 small cap healthcare stocks could boom on a new sector breakout, Wall Street analysts see up to double-digit upside in each

Boone Capital Management LLC bought a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 400,000 shares of the company'

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Floyd F. Petersen sold 3,000 shares of the firm's stock in a transaction on Monday, June 10th. The shares were sold at an average price of $41.40, for a total value of $124,200.00. Following the completion of the sale, the director now owns 78,409 shares in the company, valued at $3,246,132.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Epoch Investment Partners Inc. lifted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 348.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 592,530 shares of the company's stock af

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Floyd F. Petersen sold 500 shares of the business's stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $42.65, for a total transaction of $21,325.00. Following the completion of the sale, the director now owns 78,333 shares in the company, valued at $3,340,902.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

US Bancorp DE boosted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 2,648.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,248 shares of the company's stock after purchas

TD Asset Management Inc boosted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 449.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 793,559 shares of the company's stoc

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) - Capital One Financial increased their Q2 2024 earnings per share estimates for Amphastar Pharmaceuticals in a research note issued on Wednesday, May 22nd. Capital One Financial analyst T. Chiang now expects that the company will post e

Trexquant Investment LP bought a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 38,959 shares of the com

Charles Schwab Investment Management Inc. lifted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 7.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 379,480 shares of the company's stock af

Dimensional Fund Advisors LP reduced its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 29.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,339,142 shares of the company's stock a

Amphastar Pharmaceuticals (NASDAQ:AMPH) Trading 4.6% Higher

Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Wednesday.

BNP Paribas Financial Markets lowered its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 20.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 97,806 shares of the company's stock after se

Russell Investments Group Ltd. reduced its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 51.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 63,667 shares of the company's stock a

Mesirow Institutional Investment Management Inc. raised its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 37.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 252,8